Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Receivables (2016 - 2025)

STRATA Skin Sciences' Receivables history spans 14 years, with the latest figure at $4.1 million for Q4 2025.

  • On a quarterly basis, Receivables fell 21.55% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 21.55% decrease, with the full-year FY2025 number at $4.1 million, down 21.55% from a year prior.
  • Receivables hit $4.1 million in Q4 2025 for STRATA Skin Sciences, up from $3.5 million in the prior quarter.
  • Over the last five years, Receivables for SSKN hit a ceiling of $5.3 million in Q4 2024 and a floor of $2.9 million in Q1 2021.
  • Historically, Receivables has averaged $3.9 million across 5 years, with a median of $3.9 million in 2023.
  • Biggest five-year swings in Receivables: surged 109.7% in 2021 and later dropped 21.55% in 2025.
  • Tracing SSKN's Receivables over 5 years: stood at $3.4 million in 2021, then surged by 30.24% to $4.5 million in 2022, then fell by 0.69% to $4.4 million in 2023, then grew by 18.31% to $5.3 million in 2024, then dropped by 21.55% to $4.1 million in 2025.
  • Business Quant data shows Receivables for SSKN at $4.1 million in Q4 2025, $3.5 million in Q3 2025, and $4.0 million in Q2 2025.